vs

Side-by-side financial comparison of BLACKLINE, INC. (BL) and MADRIGAL PHARMACEUTICALS, INC. (MDGL). Click either name above to swap in a different company.

MADRIGAL PHARMACEUTICALS, INC. is the larger business by last-quarter revenue ($321.1M vs $183.2M, roughly 1.8× BLACKLINE, INC.). BLACKLINE, INC. runs the higher net margin — 2.7% vs -18.2%, a 20.9% gap on every dollar of revenue. On growth, MADRIGAL PHARMACEUTICALS, INC. posted the faster year-over-year revenue change (210.8% vs 8.1%). BLACKLINE, INC. produced more free cash flow last quarter ($26.1M vs $-133.8M).

BlackLine Systems, Inc., is an American enterprise software company that develops cloud-based services designed to automate and manage the entire financial close process as well as consolidation, invoice-to-cash, and intercompany accounting. The Los Angeles–based company has 17 offices worldwide.

Intercept Pharmaceuticals, Inc. is an American biopharmaceutical company incorporated in 2002, focusing on the development of novel synthetic bile acid analogs to treat chronic liver diseases, such as primary biliary cirrhosis (PBC) now called primary biliary cholangitis, non-alcoholic fatty liver disease, cirrhosis, portal hypertension, primary sclerosing cholangitis and also the intestinal disorder, bile acid diarrhea.

BL vs MDGL — Head-to-Head

Bigger by revenue
MDGL
MDGL
1.8× larger
MDGL
$321.1M
$183.2M
BL
Growing faster (revenue YoY)
MDGL
MDGL
+202.7% gap
MDGL
210.8%
8.1%
BL
Higher net margin
BL
BL
20.9% more per $
BL
2.7%
-18.2%
MDGL
More free cash flow
BL
BL
$159.9M more FCF
BL
$26.1M
$-133.8M
MDGL

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
BL
BL
MDGL
MDGL
Revenue
$183.2M
$321.1M
Net Profit
$4.9M
$-58.6M
Gross Margin
75.2%
Operating Margin
3.7%
-18.6%
Net Margin
2.7%
-18.2%
Revenue YoY
8.1%
210.8%
Net Profit YoY
-91.3%
1.4%
EPS (diluted)
$0.07
$-2.55

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BL
BL
MDGL
MDGL
Q4 25
$183.2M
$321.1M
Q3 25
$178.3M
$287.3M
Q2 25
$172.0M
$212.8M
Q1 25
$166.9M
$137.3M
Q4 24
$169.5M
$103.3M
Q3 24
$165.9M
$62.2M
Q2 24
$160.5M
Q1 24
$157.5M
$0
Net Profit
BL
BL
MDGL
MDGL
Q4 25
$4.9M
$-58.6M
Q3 25
$5.3M
$-114.2M
Q2 25
$8.3M
$-42.3M
Q1 25
$6.1M
$-73.2M
Q4 24
$56.4M
$-59.4M
Q3 24
$17.2M
$-107.0M
Q2 24
$76.7M
Q1 24
$10.8M
$-147.5M
Gross Margin
BL
BL
MDGL
MDGL
Q4 25
75.2%
Q3 25
75.1%
Q2 25
75.2%
Q1 25
75.5%
96.7%
Q4 24
75.6%
Q3 24
75.2%
Q2 24
74.9%
Q1 24
75.2%
Operating Margin
BL
BL
MDGL
MDGL
Q4 25
3.7%
-18.6%
Q3 25
4.3%
-39.7%
Q2 25
4.4%
-22.2%
Q1 25
2.1%
-57.8%
Q4 24
3.7%
-64.8%
Q3 24
5.0%
-187.1%
Q2 24
1.4%
Q1 24
1.1%
Net Margin
BL
BL
MDGL
MDGL
Q4 25
2.7%
-18.2%
Q3 25
3.0%
-39.8%
Q2 25
4.8%
-19.9%
Q1 25
3.6%
-53.4%
Q4 24
33.3%
-57.5%
Q3 24
10.4%
-172.0%
Q2 24
47.8%
Q1 24
6.9%
EPS (diluted)
BL
BL
MDGL
MDGL
Q4 25
$0.07
$-2.55
Q3 25
$0.09
$-5.08
Q2 25
$0.13
$-1.90
Q1 25
$0.10
$-3.32
Q4 24
$0.79
$-2.50
Q3 24
$0.27
$-4.92
Q2 24
$0.22
Q1 24
$0.17
$-7.38

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BL
BL
MDGL
MDGL
Cash + ST InvestmentsLiquidity on hand
$390.0M
$198.7M
Total DebtLower is stronger
$339.9M
Stockholders' EquityBook value
$332.3M
$602.7M
Total Assets
$1.8B
$1.3B
Debt / EquityLower = less leverage
0.56×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BL
BL
MDGL
MDGL
Q4 25
$390.0M
$198.7M
Q3 25
$419.9M
$295.7M
Q2 25
$459.1M
$186.2M
Q1 25
$479.5M
$183.6M
Q4 24
$885.9M
$100.0M
Q3 24
$725.3M
$232.7M
Q2 24
$616.6M
Q1 24
$331.4M
$622.5M
Total Debt
BL
BL
MDGL
MDGL
Q4 25
$339.9M
Q3 25
$339.8M
Q2 25
$118.4M
Q1 25
$118.0M
Q4 24
$117.6M
Q3 24
$117.1M
Q2 24
Q1 24
$116.1M
Stockholders' Equity
BL
BL
MDGL
MDGL
Q4 25
$332.3M
$602.7M
Q3 25
$328.3M
$625.7M
Q2 25
$414.0M
$696.0M
Q1 25
$417.9M
$710.6M
Q4 24
$446.7M
$754.4M
Q3 24
$367.9M
$777.2M
Q2 24
$325.8M
Q1 24
$279.8M
$850.8M
Total Assets
BL
BL
MDGL
MDGL
Q4 25
$1.8B
$1.3B
Q3 25
$1.7B
$1.4B
Q2 25
$1.8B
$1.0B
Q1 25
$1.8B
$996.6M
Q4 24
$1.8B
$1.0B
Q3 24
$1.7B
$1.1B
Q2 24
$1.9B
Q1 24
$2.1B
$1.1B
Debt / Equity
BL
BL
MDGL
MDGL
Q4 25
0.56×
Q3 25
0.54×
Q2 25
0.17×
Q1 25
0.17×
Q4 24
0.16×
Q3 24
0.15×
Q2 24
Q1 24
0.14×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BL
BL
MDGL
MDGL
Operating Cash FlowLast quarter
$26.7M
$-133.5M
Free Cash FlowOCF − Capex
$26.1M
$-133.8M
FCF MarginFCF / Revenue
14.2%
-41.7%
Capex IntensityCapex / Revenue
0.3%
0.1%
Cash ConversionOCF / Net Profit
5.46×
TTM Free Cash FlowTrailing 4 quarters
$161.5M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BL
BL
MDGL
MDGL
Q4 25
$26.7M
$-133.5M
Q3 25
$63.8M
$79.8M
Q2 25
$32.3M
$-47.1M
Q1 25
$46.7M
$-88.9M
Q4 24
$43.8M
$-104.5M
Q3 24
$55.9M
$-67.0M
Q2 24
$40.7M
Q1 24
$50.4M
$-149.2M
Free Cash Flow
BL
BL
MDGL
MDGL
Q4 25
$26.1M
$-133.8M
Q3 25
$63.3M
$79.0M
Q2 25
$31.4M
Q1 25
$40.8M
Q4 24
$43.0M
$-104.7M
Q3 24
$55.5M
$-67.8M
Q2 24
$40.0M
Q1 24
$50.1M
$-149.5M
FCF Margin
BL
BL
MDGL
MDGL
Q4 25
14.2%
-41.7%
Q3 25
35.5%
27.5%
Q2 25
18.2%
Q1 25
24.4%
Q4 24
25.4%
-101.3%
Q3 24
33.5%
-109.0%
Q2 24
24.9%
Q1 24
31.8%
Capex Intensity
BL
BL
MDGL
MDGL
Q4 25
0.3%
0.1%
Q3 25
0.3%
0.3%
Q2 25
0.6%
0.0%
Q1 25
3.6%
0.0%
Q4 24
0.4%
0.2%
Q3 24
0.2%
1.3%
Q2 24
0.4%
Q1 24
0.2%
Cash Conversion
BL
BL
MDGL
MDGL
Q4 25
5.46×
Q3 25
12.07×
Q2 25
3.90×
Q1 25
7.72×
Q4 24
0.78×
Q3 24
3.24×
Q2 24
0.53×
Q1 24
4.66×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

BL
BL

Subscription And Circulation$173.2M95%
Technology Service$10.0M5%

MDGL
MDGL

Rebates Customer Fees Credits Co Pay Assistance And Other$208.5M65%
Other$76.0M24%
Chargebacks Discounts For Prompt Pay And Other Allowances$36.6M11%

Related Comparisons